Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.

摘要: Antimicrobial therapy can have a significant impact in the treatment of acute infectious exacerbations patients with chronic bronchitis, whom repeated episodes are common. The aim this randomised, double-blind, double-dummy, parallel group study was to compare efficacy and safety oral gatifloxacin (200 400 mg once daily) administered for 5 days co-amoxiclav (500 amoxicillin/125 clavulanic acid t.i.d.) 10 414 adult exacerbation bronchitis. Overall clinical response rates (cure plus improvement) were 86.2%, 79.4% 81.7% 200 mg, groups, respectively, equivalence hypothesis used statistical analysis showed equivalent both compared co-amoxiclav. same true bacterial response, eradication or presumed causative pathogens achieved 87.5%, 87.3% 79.1% cases respectively. All treatments well tolerated, nature frequency treatment-related adverse events similar all groups. results show that is safe effective agent bronchitis experiencing an exacerbation.